Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

amsterdam the netherlands

ESC Congress 2023: 4 key sessions scheduled for world’s largest gathering of cardiology professionals

The four-day event in Amsterdam officially begins on Friday, Aug. 25. Read our sneak preview of some of the conference's key sessions. 

Thumbnail

Missed opportunities: Many high-risk patients still not taking aspirin to prevent CVD

Aspirin is known to be an effective, affordable way to prevent cardiovascular disease.

cardiologist doctor physician patient black diverse hypertension

Chest pain one year after a heart attack linked to lower odds of survival

A new study in the Journal of the American Heart Association focused on data from more than 18,000 patients.

A complete list of the European Society of Cardiology (ESC) 2023 Congress late-breaking Hot Line sessions. #ESCCongress

ESC Congress 2023 to feature 30 late-breaking clinical trials

The European Society of Cardiology's annual meeting is scheduled for Aug. 25-28, 2023, in Amsterdam.

the words "FDA recall" on a board

FDA announces yet another recall, the fifth of 2023, for troubled heart devices

The latest Class I recall is due to mechanical issues that can cause the devices to stop charging their batteries. 

doctor with overweight patient who may be treated with TAVR or surgery

Weight loss drug semaglutide could boost heart health of up to 93M patients in US alone

Researchers have recently determined that the medication, originally developed to treat diabetes, can contribute to weight loss and reduce a patient's MACE risk by up to 20%. 

FDA announces fourth recall of 2023 for troubled heart devices

This latest recall was brought on by electrical failures and includes more than 4,500 devices. There have been 26 complaints due to the issue but no reported injuries or deaths. 

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients

Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.